The fraction of the drug dose that reaches the systemic circulation is the drug bioavailability.

Drug products that have comparable rate and extent of absorption are considered bioequivalent.

Assessment of the bioequivalence of drug products is necessary to make sure that the new drug products have bioavailability comparable to that of the innovator drug products.